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Abstract
We recently observed that the addition of caffeine (a nonselective adenosine receptor antagonist) 
to a 20% ethanol solution significantly altered the intoxication profile of male C57BL/6J (B6) 
mice induced by voluntary binge-like consumption in the ‘Drinking-in-the-Dark’ (DID) paradigm. 
In the current study, the roles of A1 and A2A adenosine receptor subtypes, specifically, in binge-
like ethanol consumption and associated locomotor effects were explored. Adult male B6 mice 
(PND 60-70) were allowed to consume 20% ethanol (v/v) or 2% sucrose (w/v) for 6 days via DID. 
On day 7, mice received a systemic administration (i.p.) of the A1 antagonist DPCPX (1, 3, 6 mg/
kg), the A2A antagonist MSX-3 (1, 2, 4 mg/kg), or vehicle immediately prior to fluid access in 
DID. Antagonism of the A1 receptor via DPCPX was found to dose-dependently decrease binge-
like ethanol intake and associated blood ethanol concentrations (p’s < 0.05), although no effect 
was observed on sucrose intake. Antagonism of A2A had no effect on ethanol or sucrose 
consumption, however, MSX-3 elicited robust locomotor stimulation in mice consuming either 
solution (p’s < 0.05). Together, these findings suggest unique roles for the A1 and A2A adenosine 
receptor subtypes in binge-like ethanol intake and its associated locomotor effects.
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1. Introduction
Binge ethanol (alcohol) consumption, defined by levels of intake resulting in significant 
intoxication (blood alcohol concentration ≥ 80 mg/dl) within a discrete period of ≤ 2 hrs 
(NIAAA), is a common form of problematic alcohol use associated with an elevated risk for 
numerous negative consequences and may even mark progression towards more severe 
alcohol use problems (Chassin et al., 2002, Viner and Taylor, 2007). Therefore, enhancing 
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our understanding of the neurobehavioral underpinnings of binge drinking will offer insight 
on the systems it affects and elucidate the potential for intervention and/or treatment.
Much of the substance abuse literature has given attention to dopamine as a crucial 
neurotransmitter in drug and alcohol consumption and responses (Di Chiara, 1999, Koob, 
1992, Le Foll et al., 2009). However, relatively little acknowledgement has been given to the 
observation that adenosine signaling has the capacity to regulate the efficiency of dopamine 
neurotransmission, as well as the release and binding efficiency of other neurotransmitters 
(Fredholm et al., 2005). This is relevant for the alcohol abuse research field as in vitro 
studies have shown that acute alcohol exposure increases extracellular adenosine levels, 
indirectly, by inhibition of adenosine’s transporter, endonucleoside transporter 1 (ENT1) 
(Nagy et al., 1990, Allen-Gipson et al., 2009).
Preclinical work with rodents suggests that adenosine signaling, indeed, plays a role in 
alcohol consumption (Choi et al., 2004, El Yacoubi et al., 2003b, Naassila et al., 2002, 
Thorsell et al., 2007, Di Bonaventura et al., 2012, Houchi et al., 2013, Arolfo et al., 2004, 
Adams et al., 2008, Houchi et al., 2008, Nam et al., 2013) and that this relationship may be 
moderated, in part, by the influence of adenosine mechanisms on alcohol’s motor-impairing 
and sedative effects (Choi et al., 2004, Di Bonaventura et al., 2012, Houchi et al., 2013, 
Houchi et al., 2008). However, alcohol intakes were largely low-to-moderate in these studies 
(however, see Houchi et al., 2008) and blood alcohol concentrations following drinking 
were never assessed. In addition, a significant portion of this work has been limited to 
knockout models or operant paradigms. Behavioral and quantitative genetic studies in 
rodents suggest that binge-like alcohol consumption is a distinct phenotype (Fritz et al., 
2014b, Bell et al., 2006, Iancu et al., 2013). Therefore, elucidating its neurochemical/
biological underpinnings will be necessary to more completely understand this form of 
excessive alcohol drinking. To our knowledge, no study examining the influence of 
adenosine receptor pharmacology on voluntary binge-like drinking currently exists. 
Recently, we demonstrated that the addition of caffeine (a nonselective adenosine receptor 
antagonist) to a 20% ethanol solution significantly altered the intoxication profile of male 
C57BL/6J (B6) mice induced by voluntary binge-like consu1mption via the ‘Drinking-in-
the-Dark’ (DID) paradigm (Fritz et al., 2014a). The DID paradigm has been validated as a 
‘binge’ paradigm as mice will consistently drink alcohol to reach blood alcohol 
concentrations in excess of 80-100 mg/dl in a short period of 2 hours (aligning with the 
aforementioned NIAAA definition of binge drinking) and demonstrate significant motor and 
cognitive impairment as a result of alcohol consumption in this paradigm (Sprow and 
Thiele, 2012, Fritz et al., 2014a). Specifically, we observed that the addition of caffeine 
attenuated ataxia and sedation induced by voluntary binge alcohol consumption, although 
caffeine did not influence alcohol-induced anxiolysis, memory interference, or alcohol 
intake. These findings suggest that nonspecific adenosine receptor antagonism via caffeine 
influences specific facets of binge-like alcohol intoxication in the DID model, thus 
implicating a role for adenosine signaling in these behaviors. Because caffeine acts upon the 
adenosine system as a nonselective antagonist (Fredholm et al., 1999), it is unclear how 
specific adenosine receptor subtypes might influence binge-like alcohol drinking or resultant 
intoxication as effects at one receptor may compete with those at another. As such, we chose 
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to explore the role of the A1 and A2A receptor subtypes, specifically in binge-like alcohol 
intake of male B6 mice via the DID model and its locomotor consequences.
2. Methods
2.1 Animals
Adult male (PND 56 ± 3) B6 mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME) and allowed 10-14 days to acclimate the colony room and single housing prior 
to experimentation. Animals were maintained on a 12-hour reverse light/dark cycle with 
lights OFF at 0700 with temperature and humidity held constant near 20° C and 50%, 
respectively. Food and water were available ad libitum. Principles of laboratory animal care 
were followed and experiments were performed under a protocol approved by the IUPUI 
School of Science Institutional Animal Care and Use Committee.
2.2 Drugs and Drinking Solutions
The adenosine A1 receptor antagonist 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) and the 
A2A receptor antagonist 3,7-Dihydro-8-[(1E)-2-(3-Methoxyphenyl)ethenyl]-7-methyl-3-[3-
(phosphonooxy)propyl-1-(2-propynyl)-1H-purine-2,6-dione disodium salt hydrate (MSX-3) 
were both obtained from Sigma Aldrich (St. Louis, MO). Vehicle for DPCPX was a 
maximal concentration of 30% (v/v) 0.1 M NaOH in sterile physiological saline for the 
highest administered dose (6 mg/kg). For MSX-3, the maximal concentration of NaOH was 
16% (v/v) for the highest dose administered (4 mg/kg). The vehicle control groups had the 
respective maximal concentration of NaOH in saline to control for any effects the highest 
concentration of NaOH may have had on drinking or locomotor activity. DPCPX is 1,000-
fold more selective for the A1 receptor over the A2A receptor (Fredholm and Lindström, 
1999). MSX-3 is a prodrug for MSX-2, which has demonstrated 100-fold selectivity for A2A 
over A1 in both rat and human tissue, with no activity at A2B or A3 subtypes (Sauer et al., 
2000, Solinas et al., 2005). For drinking solutions, ethanol (190 proof; Pharmco Inc., 
Brookfield, CT) was diluted to 20% (v/v) in tap water and sucrose (Sigma-Aldrich, St. 
Louis, MO) was dissolved in tap water to 2% (w/v).
2.3 Drinking in the Dark
We used a DID procedure slightly modified from the original version (Rhodes et al., 2005). 
Beginning 3 hours into the dark cycle, singly housed male B6 mice had their water bottles 
replaced by a 10 ml sipper tube containing either an alcohol or sucrose solution for 2 hours. 
During this period, the only fluid available was the designated test fluid. As is common in 
preclinical alcohol studies, sucrose consumption was assessed in addition to ethanol to 
evaluate whether either antagonist influenced the intake of a natural reward/reinforcer, 
allowing for the determination of whether the drugs’ effects were ethanol-specific and 
simply did not influence hedonic processes (Sprow and Thiele, 2012).
2.4 Home Cage Locomotor Activity Monitors
Details concerning the exact monitors (Columbus Instruments Inc., Columbus, OH) used in 
the current study were previously published (Linsenbardt and Boehm, 2012). Each day, 
locomotor activity was measured in each mouse’s home cage during the 2 hr DID session. 
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Monitoring activity in this manner allowed for determination of whether the effects of either 
compound on locomotion could account for fluid intake differences. Furthermore, locomotor 
activity during alcohol intoxication is also considered a relevant phenotype to address as it 
reflects sensitivity to alcohol’s motor-impairing or – stimulating effects; phenotypes that 
have been associated with a propensity for high/low alcohol consumption (Colombo et al., 
1998, Risinger et al., 1994, Fritz et al., 2013, Kurtz et al., 1996).
2.5 Procedure
Mice acquired ethanol (n = 79) or sucrose (n = 75) drinking via DID over 6 days. Prior to 
drug challenge on day 7, mice were counterbalanced for ethanol or sucrose consumption as 
well as locomotor activity prior to drug dose assignment, and then weighed and injected 
with DPCPX (0, 1, 3, 6 mg/kg, i.p.) or MSX-3 (0, 1, 2, 4 mg/kg, i.p.) immediately prior to 
fluid access. This study employed a between-subjects design where each mouse had access 
to only either sucrose or ethanol during DID and received a single injection of the assigned 
drug on day 7. Fluid intakes were recorded every 30 minutes by removing the tube from the 
cage and reading the volume at eye level. Additional tubes filled with ethanol and sucrose 
were placed on empty cages and were also read every 30 minutes to control for the spillage 
produced by multiple readings during the session. The average leakage volumes for ethanol 
and sucrose were controlled for in the analysis of fluid intakes. Periorbital blood samples 
were taken from mice that had access to ethanol immediately following the 2 hr access 
period for later blood alcohol level determination via an AM1 Analox Alcohol Analzyer 
(Analox Instruments, Lunenburg, MA). Measuring blood alcohol content is crucial to 
determine whether mice 1) are indeed ingesting the alcohol solution rather than causing it to 
spill out into the cage and 2) verify that high levels of intake are indeed producing BECs that 
are considered to be ‘binge’ levels (≥ 80 mg/dl) in vehicle-treated mice using the DID 
paradigm.
2.6 Statistical Analysis
Ethanol and sucrose data were analyzed separately. Intake and locomotor data during 
acquisition were analyzed via repeated measures ANOVA with dose and day as factors. 
Intake and locomotion data on day 7 were also analyzed via repeated measures ANOVA, but 
with dose and time (each 30 min bin) as factors. Neuman-Keuls post-hoc statistics were run 
where applicable.
3. Results
3.1 Acquisition (days 1-6)
Drinking and locomotor activity data during DID acquisition over days 1-6 for alcohol and 
sucrose groups are represented in Figure 1. Dose groups were counterbalanced so that they 
did not differ in alcohol/sucrose intake or locomotor activity during this period (all p’s > 
0.17).
3.2 Test Day
3.2.1 Alcohol intake and locomotor activity—Systemic administration of the A1 
antagonist DPCPX was found to significantly dose-dependently reduce alcohol intake [F3,34 
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= 5.34, p < 0.01] with the 3 and 6 mg/kg doses being effective relative to vehicle (post-hoc 
p ’s < 0.05; Figure 2A). Although the dose × time interaction was not statistically significant 
(p > 0.05), we also analyzed intake during the first 30 min portion of DID drinking 
separately on the basis of previous observations that male B6 mice consume alcohol most 
heavily within this early phase of DID (Wilcox et al., 2014, Linsenbardt and Boehm, 2014). 
The 6 mg/kg dose effectively reduced early alcohol drinking [F3,34 = 87.71, p < 0.01], an 
effect that appears to be largely responsible for its reduction in overall alcohol intake. 
Furthermore, DPCPX significantly reduced attained BACs [F3,34 = 3.01, p < 0.05] with the 
6 mg/kg dose reducing BACs below vehicle levels (post-hoc p < 0.05; Figure 3A). 
Locomotor activity during alcohol drinking in DID was unaffected by DPCPX (p > 0.05; 
Figure 2C) and dose did not interact with time (p > 0.05).
In contrast, the A2A antagonist MSX-3 had no effect on early (first 30 min) or overall 
alcohol intake (p’s > 0.05; Figure 2B) and BACs were also unaffected (p > 0.05; Figure 3B). 
However, MSX-3 dose-dependently increased locomotion during ethanol consumption in 
DID [F3,37 = 7.96, p < 0.001] with the 2 and 4 mg/kg doses producing significant 
stimulation (post-hoc p’s < 0.05; Figure 2D). The dose × time interaction was not 
statistically significant (p > 0.05).
3.2.2 Sucrose intake and locomotor activity—Antagonism of the A1 adenosine 
receptor via systemic administration of DPCPX did not alter early (first 30 min) or overall 
sucrose intake and dose did not interact with time (p’s > 0.05; Figure 4A). However DPCPX 
did stimulate locomotor activity [F3,31 = 4.07, p < 0.05] with the 1 and 3 mg/kg doses being 
effective (post-hoc p ’s < 0.05; Figure 4B). A significant dose × time interaction [F9,93 = 
2.62, p < 0.01] also revealed that these effects occurred early (30 min) and late (120 min) in 
the DID test (p’s < 0.05).
Antagonism of the A2A adenosine receptor via systemic administration of MSX-3 did not 
alter early (first 30 min) or overall sucrose intake and dose did not interact with time (p’s > 
0.05; Figure 4B). Overall locomotor activity was also found to be stimulated by MSX-3 
during sucrose drinking in DID [F3,34 = 5.02, p < 0.01] with only the 4 mg/kg dose 
producing significant stimulation (p < 0.01). A significant dose × time interaction [F9,102 = 
3.73, p < 0.001] also revealed that all doses of MSX-3 stimulated locomotion in the first 30 
minutes relative to vehicle-treated mice with the 4 mg/kg dose having the most robust effect 
(p ’s < 0.05). Furthermore, only the 4 mg/kg dose effectively promoted locomotor 
stimulation at the 60 min time point (p < 0.01).
4. Discussion
The present study found that antagonism of the adenosine A1 receptor significantly reduced 
alcohol consumption below binge levels (6 mg/kg dose of DPCPX reduced mean BAC 
below 80 mg/dl), however, A2A antagonism had no effect. These observations were specific 
to binge-like alcohol consumption as sucrose intake was not affected by either compound. 
Furthermore, antagonism of the A2A receptor significantly stimulated locomotor activity in 
alcohol- and sucrose-consuming mice, with a more robust effect in alcohol-consuming mice. 
However, only mice consuming sucrose demonstrated locomotor stimulation via A1 
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antagonism. Together, these results suggest different roles for these receptors in binge-like 
alcohol drinking and associated locomotor activity.
Previous preclinical studies have demonstrated a role for adenosine signaling in alcohol 
consumption. Although there are 4 known adenosine receptors, the most studied are the 2 
prominent adenosine receptor subtypes in the central nervous system, the A1 and A2A 
receptors, and activation of these subtypes has been shown to significantly influence the 
release and/or binding efficiency of many neurotransmitters (Fredholm et al., 2005). As 
such, these receptor subtypes have been the primary focus of study in alcohol abuse research 
in addition to ENT1. Genetic deletion of ENT1 in mice, presumably shunting alcohol-
induced increases in extracellular adenosine, elevates alcohol consumption in a 2-bottle 
choice paradigm (Choi et al., 2004). Pharmacological blockade of A2A receptors has been 
shown to both increase (Arolfo et al., 2004, Di Bonaventura et al., 2012) and decrease 
(Adams et al., 2008, Thorsell et al., 2007) alcohol responding/consumption in rats. One 
recent study in mice suggests that goal-directed behavior in operant responding for alcohol 
may be mediated in part by the dorsomedial striatum as local A2A antagonism increases 
responding for alcohol (Nam et al., 2013). Conversely, pharmacological A2A activation via 
agonists reduces alcohol responding/consumption in operant paradigms as well as 2-bottle 
choice drinking in rats and mice (Di Bonaventura et al., 2012, Houchi et al., 2013, Houchi et 
al., 2008). Furthermore, one study with A2A knockout mice generated on a CD1 background 
found increased alcohol consumption in a 2-bottle choice paradigm (Naassila et al., 2002), 
however a later study with knockouts generated on a B6 background found no effect of A2A 
deletion on alcohol intake (Houchi et al., 2008). When a number of these studies evaluated 
the role of the A1 receptor, however, genetic deletion or pharmacological antagonism was 
found to have no effect on responding for/consumption of alcohol (Adams et al., 2008, 
Arolfo et al., 2004, Houchi et al., 2013).
Collectively, these observations are strikingly different from the findings of the current 
study. We found no evidence of A2A antagonism on either alcohol or sucrose intake in the 
DID paradigm and an alcohol-specific decrease in intake via A1 blockade with the 6 mg/kg 
dose of DPCPX significantly reducing both alcohol intake and BAC. Although the 3 mg/kg 
dose of DPCPX was found to decrease total alcohol intake over the 2 hr session, this did not 
translate to a significantly reduced BAC level relative to vehicle. One reason for this may be 
that the most prominent and discernable dose effect of DPCPX is clearly within the first 30 
minutes of fluid access (Figure 2A). As mentioned earlier, only the 6 mg/kg dose 
significantly reduced alcohol intake in this early time bin. Therefore, it may not be 
surprising that the observed effects on BAC mirror the major drug effect, which is clearly 
demonstrated within the first 30 minute time bin. Although neither compound was found to 
influence sucrose intake, it is important to note that mice did consume larger volumes of the 
sucrose solution than the ethanol solution in this study, raising the possibility of whether a 
ceiling effect existed for sucrose-drinking mice. Our group has previously used a higher 
concentration of sucrose (5% w/v) in the DID paradigm and found that mice consumed far 
more fluid (~120 ml/kg) (Melón and Boehm II, 2011) than what was observed with 2% 
sucrose in the present study (~70 ml/kg). Thus, although we cannot rule out the possibility 
that the 2% sucrose solution may have been too rewarding to observe an effect of either 
antagonist, we feel that this is unlikely in light of this previous finding.
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To our knowledge, this is the first observation of A1 receptor manipulation influencing 
alcohol consumption. There are a number or reasons why our findings do not appear to align 
with those of previous studies. First, although prior work suggests a prominent role for the 
A2A receptor in alcohol seeking and consumption, this may be dependent on the rodent 
genotype. As mentioned above, Houchi et al. (2008) were not able to replicate the elevated 
alcohol intake of A2A knockout mice bred on a CD1 background when they instead bred 
mice on a B6 background. This may also offer an explanation as to why A2A blockade was 
ineffective in manipulating the binge-like alcohol intake of male B6 mice in the current 
study. Second, although the BACs of animals were not evaluated in any of the 
aforementioned studies, the alcohol intake levels observed were largely low to moderate 
(however, see Houchi et al., 2008) and therefore likely below binge levels (< 80 mg/dl). The 
current study employed the binge-like drinking DID paradigm and our vehicle control 
groups consumed > 4.2 g/kg in 2 hrs and reached BACs ≥ 87 mg/dl, on average (Figures 1A 
and 2). Therefore, A1 receptors may be more influential in regulating higher, binge-like 
alcohol intake. In addition, the extent of a subject’s alcohol consumption history may 
influence sensitivity to pharmacological manipulation of A1 or A2A receptors. In contrast to 
the current study, these previous studies largely employed alcohol drinking paradigms that 
spanned the course of weeks. More protracted alcohol consumption such as this may have 
influenced adenosine receptor makeup/number/sensitivity in a way that mitigated the 
influence of the A1 receptor. Indeed, one previous study showed that pre-treatment with 
DPCPX attenuated the development of rapid tolerance to alcohol’s ataxic effect in mice 
(Batista et al., 2005), suggesting that A1 receptor activation is involved in the adaptive 
response to alcohol intoxication. Our lab and others have shown that longer DID access 
(~2-4 weeks opposed to 1 week) produces ataxic tolerance (Linsenbardt et al., 2011), 
alterations in associated locomotion (Linsenbardt and Boehm, 2014, Linsenbardt et al., 
2011, Fritz et al., 2014a), and the rate of alcohol intake (Wilcox et al., 2014, Linsenbardt and 
Boehm, 2014), perhaps indicating that the duration of alcohol access in this model may also 
alter sensitivity to one or both of these compounds. In addition, animals in our study were 
freely consuming alcohol in their home cage versus operant chambers in other studies. This 
may reflect different roles for the A1 and A2A receptors in voluntary alcohol consumption 
versus alcohol reinforcement, although future studies should more directly address this 
possibility. In the context of this systemic administration study, it is also important to note 
that A1 and A2A receptors are present in the periphery, largely regulating cardiovascular and 
inflammatory processes (Albrecht-Küpper et al., 2012, Deharo et al., 2012, Williams and 
Cronstein, 2012, Antonioli et al., 2013). Future efforts employing brain-region specific 
administration will seek to clarify the extent to which the observed effects are mediated by 
central or perhaps, peripheral effects. Finally, it is worth noting that evaluating A1 or A2A 
agonists as well in the current study could clarify these results further, offering more 
information on how activity through these receptor subtypes may influence the phenotypes 
examined. However, we chose to only use antagonists due to the aforementioned sedative 
properties of adenosine signaling and systemic administration of agonists would raise 
concerns over competing sedative responses. Moreover, as alcohol has been demonstrated to 
produce motor impairment through these adenosine receptor subtypes (Dar, 2002, El 
Yacoubi et al., 2003a), evaluating their systemic effects during alcohol consumption 
appeared problematic. As mentioned above, however, central administration with 
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microinjection techniques may offer a more appropriate way to evaluate the effects of 
adenosine agonists.
The role of adenosine signaling in alcohol’s motor effects has been more thoroughly 
characterized. A1 receptors, in particular, have been implicated in alcohol-induced ataxia 
with both systemic and central antagonist/agonist pretreatment reducing/accentuating ataxia 
following an acute injection of alcohol (Barwick and Dar, 1998, Connole et al., 2004). In 
addition, activation of the A1 receptor has been shown to be an important factor in 
developing tolerance to alcohol’s ataxic effects as systemic pretreatment with DPCPX 
attenuates rapid tolerance development (Batista et al., 2005). A1 receptors are pervasive 
throughout the brain with higher concentrations in cortex and hippocampus, although they 
are very prominent in the cerebellum (Goodman and Synder, 1982, Fastbom et al., 1987), 
where they likely exert the greatest influence on alcohol-induced ataxia (Dar, 1996; 2002). 
A2A receptors on the other hand appear to be more influential in alcohol-induced sedation, 
with antagonist pretreatment or genetic deletion in knockout mice reducing alcohol-induced 
hypnosis in the loss of righting reflex task (El Yacoubi et al., 2003b, Naassila et al., 2002). 
A2A knockout mice bred on a CD1 background also demonstrate significantly greater acute 
locomotor stimulation following a 1.5 g/kg dose of alcohol (i.p.), however, this was not 
observed in mice bred on a B6 background (Houchi et al., 2008). We observed that both A1 
and A2A antagonism significantly stimulated locomotor activity in mice consuming sucrose, 
however only A2A antagonism produced significant locomotor stimulation in mice 
consuming alcohol. The observation of global locomotor stimulation is not surprising as 
MSX-3 has previously been demonstrated to stimulate locomotion in rats (Müller et al., 
1998, Nagel et al., 2003). A2A receptors are highly localized to the striatum (Rosin et al., 
1998), a region where dopaminergic input is strongly involved in motor activity (Wickens, 
1990). Interestingly, the stimulant effect of MSX-3 appeared to be more efficient in mice 
consuming alcohol as both the 2 and 4 mg/kg doses produced robust stimulation whereas 
only the 4 mg/kg dose did so in sucrose-consuming mice. Although the baseline activity of 
alcohol-consuming mice may have been lower than that of sucrose mice, the increase in 
activity relative to control mice was nevertheless more robust and the 2 mg/kg dose 
effectively elicited stimulation. One reason this may be is that binge-like alcohol 
consumption could have produced an increase in striatal dopamine levels that when coupled 
with A2A antagonism, resulted in a more pronounced stimulant response. Indeed, voluntary 
binge-like alcohol consumption has been demonstrated to produce an increase in dopamine 
levels in the nucleus accumbens (part of the ventral striatum) of male B6 mice (Szumlinski 
et al., 2007). It is not clear why the low and moderate doses of DPCPX produced locomotor 
stimulation only in mice consuming sucrose. One possibility is that alcohol consumption 
may have positively modulated adenosine signaling in some capacity thus, competing with 
the ability of DPCPX to induce locomotor stimulation. As mentioned above, the A1 receptor 
is highly involved in the motor effects of alcohol intoxication and alcohol consumption may 
therefore have competed with the locomotor-stimulating effect of these doses of DPCPX.
Adenosine signaling interacts with many other neurotransmitter systems (Fredholm et al., 
2005), although we speculate that its associative role with dopamine signaling may account 
for some of effects observed here and elsewhere on alcohol consumption and locomotor 
activity. The A1 and A2A receptor subtypes are the most prominent in the central nervous 
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system and activation of these receptors has been shown to have antagonistic effects on 
dopamine release and binding potential for D1 and D2 receptors (Fredholm et al., 2005, Fuxe 
et al., 2010). This is in large part because adenosine and dopamine receptors can form 
functional heterodimers, with A1 associating with the D1 receptor and A2A associating with 
D2 receptor. Interestingly, one previous study observed that pharmacological activation via 
the D1 partial agonist SKF 38393 decreases 1-hr limited access alcohol consumption in male 
Wistar rats whereas the D2 agonist quinpirole had no effect (Linseman, 1990). These 
observations may reflect what was observed in the current study where antagonism of the A1 
receptor may have released adenosinergic inhibition of dopamine binding to the D1 receptor 
and thus, attenuated alcohol consumption while no effect of A2A antagonism on binge like 
alcohol consumption may fall in line with a lack of D2 receptor influence. However, it 
should be noted that other studies have shown that pharmacological activation of both D1 
and D2 receptors can influence alcohol consumption/seeking in rodents (Dyr et al., 1993, Ng 
and George, 1994, Ingman et al., 2006, Hodge et al., 1997, Silvestre et al., 1996, Bono et al., 
1996). Although, these studies employed longer alcohol access periods (4+ hrs) or operant 
paradigms and may therefore reflect a form of alcohol consumption different from a 
voluntary binge model.
As A1-D1 and A2A-D2 heterodimers are both found on GABA neurons and glutamate 
synapses in striatopallidal circuitry (Azdad et al., 2009, Ferré et al., 2002, Franco et al., 
2007), this complex dopamine-adenosine interaction has the capacity to regulate basal 
ganglia output, an effect which may underlie the observed locomotor stimulation in the 
current study by both antagonists. Furthermore, a previous study found that A2A antagonism 
specifically in the dorsomedial, but not dorsolateral striatum, increased goal-directed alcohol 
seeking in mice (Nam et al., 2013), suggesting that this behavior can be regulated in some 
capacity by striatal adenosine signaling. Although we observed no effect of A2A antagonism 
in the current study, global antagonism by systemic administration may have produced 
competing effects in other brain regions. Furthermore, it is also possible that A1 receptors 
specifically located in striatal subregions may regulate binge-like drinking, mirroring our 
findings with systemically administered drug. Future studies aimed at microinjecting 
antagonists into striatal subregions will explore these possibilities.
In conclusion, we have demonstrated that antagonism of the A1 receptor produces an 
alcohol-specific decrease in binge-like intake via the DID model. Although A2A receptor 
antagonism did not influence alcohol or sucrose intake, it produced locomotor stimulation 
that was particularly robust in alcohol-consuming mice. These findings suggest that A1 
receptors play a regulatory role in binge-like alcohol consumption whereas A2A receptors 
influence its locomotor effects during intoxication.
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Highlights
• The adenosine A1 antagonist DPCPX significantly decreased binge-like alcohol 
intake
• The A2A antagonist MSX-3 did not significantly influence alcohol or sucrose 
intake
• MSX-3 elicited particularly robust locomotor stimulation in mice consuming 
alcohol
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Figure 1. 
A) Fluid intake for 20% (v/v) alcohol or 2% (w/v) sucrose and B) home cage locomotor 
activity during the 6-day DID acquisition period. n’s = 75-79. Subsequent dose group 
assignment for both drugs was counterbalanced on both of these measures so that no 
baseline differences existed.
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Figure 2. 
Alcohol (20%) consumption following systemic administration of A) the A1 antagonist 
DPCPX [0, 1, 3, 6 mg/kg; i.p.] or B) the A2A antagonist MSX-3 [0, 1, 2, 4 mg/kg; i.p.] over 
the course of the 2-hr DID session on day 7. Home cage locomotor activity following 
administration of C) DPCPX and D) MSX-3 is also shown for the 2-hr DID session on day 
7. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control group; #p < 0.05 verus 1 
mg/kg group. n’s = 8-12.
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Figure 3. 
Blood alcohol concentrations (BACs) following the 2-hr drug challenge DID session on day 
7. BACs following A) DPCPX [0, 1, 3, 6 mg/kg; i.p.] or B) MSX-3 [0, 1, 2, 4 mg/kg; i.p.] 
administration. *p < 0.05 versus vehicle control group. n’s = 8-12.
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Figure 4. 
Sucrose (2%) consumption following systemic administration of A) the A1 antagonist 
DPCPX [0, 1, 3, 6 mg/kg; i.p.] or B) the A2A antagonist MSX-3 [0, 1, 2, 4 mg/kg; i.p.] over 
the course of the 2-hr DID session on day 7. Home cage locomotor activity following 
administration of C) DPCPX and D) MSX-3 is also shown for the 2-hr DID session on day 
7. *p < 0.05, **p < 0.01 versus vehicle control group. n’s = 8-11.
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